Immunovant

IMVT · NASDAQ

$28.59+$0.97 (+3.51%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $27.62

Latest news

NewsOct 14, 4:59 AM ET
Immunovant Q1 2027 Earnings Call: Complete Transcript
Press releaseOct 12, 7:35 PM ETPRNewswire
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
Press releaseOct 11, 5:43 PM ETBusiness Wire
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
NewsOct 8, 8:07 AM ETAvi Kapoor
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Press releaseSep 25, 1:55 PM ETPRNewswire
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
NewsSep 23, 9:03 AM ETVandana Singh
Immunovant Ends Autoimmune Skin Disorder Program
Press releaseSep 23, 7:00 AM ETGlobe Newswire
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
NewsSep 17, 8:18 AM ET
Immunovant Q1 2027 Earnings Call: Complete Transcript
Press releaseAug 19, 7:52 PM ETPRNewswire
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
Press releaseAug 6, 7:00 AM ETGlobe Newswire
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
Press releaseJul 23, 4:05 PM ETGlobe Newswire
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
NewsMay 21, 12:07 PM ETAvi Kapoor
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
NewsMay 20, 1:09 PM ETEvette Mitkov
Immunovant Stock Surges Despite Disappointing Earnings Miss
NewsMay 20, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsMay 20, 12:16 PM ETAvi Kapoor
Crude Oil Down 5%; Lowe's Posts Upbeat Earnings
NewsMay 20, 10:02 AM ETAvi Kapoor
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
NewsMay 20, 8:06 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsMay 20, 7:11 AM ET
Earnings Scheduled For May 20, 2026
Press releaseMay 20, 7:00 AM ETGlobe Newswire
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
Press releaseMay 11, 4:05 PM ETGlobe Newswire
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
NewsApr 2, 7:17 AM ET
Market-Moving News for April 2nd
Press releaseApr 2, 5:00 AM ETGlobe Newswire
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Press releaseFeb 17, 10:48 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
NewsFeb 6, 7:02 AM ET
Immunovant Q3 Earnings Assessment
Press releaseFeb 6, 7:00 AM ETGlobe Newswire
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Press releaseJan 23, 5:25 PM ETGlobe Newswire
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Press releaseJan 5, 12:00 PM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
NewsDec 11, 1:39 PM ETVandana Singh
Roivant Signals Major Pipeline Momentum With Accelerated Timelines
NewsDec 11, 12:18 PM ETAvi Kapoor
Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday
Press releaseDec 11, 1:29 AM ETGlobe Newswire
Immunovant Announces Pricing of $550 Million Common Stock Financing
Press releaseNov 10, 7:00 AM ETGlobe Newswire
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
NewsNov 7, 9:02 AM ET
Insights into Immunovant's Upcoming Earnings
Press releaseOct 27, 4:10 PM ETGlobe Newswire
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Press releaseSep 12, 4:22 PM ETBusiness Wire
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
Press releaseSep 3, 1:01 PM ETGlobe Newswire
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Press releaseSep 3, 12:57 PM ETGlobe Newswire
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Press releaseAug 29, 5:31 PM ETPRNewswire
IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
Press releaseAug 27, 8:33 PM ETBusiness Wire
IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm
Press releaseAug 13, 10:05 PM ETBusiness Wire
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT
Press releaseAug 11, 7:00 AM ETGlobe Newswire
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025
Press releaseMay 29, 5:10 PM ETPRNewswire
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm
Press releaseMay 21, 8:48 PM ETBusiness Wire
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Immunovant Q1 2027 Earnings Call: Complete Transcript

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law

Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)

Immunovant Ends Autoimmune Skin Disorder Program

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Immunovant Q1 2027 Earnings Call: Complete Transcript

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

Immunovant Stock Surges Despite Disappointing Earnings Miss

12 Health Care Stocks Moving In Wednesday's Intraday Session

Crude Oil Down 5%; Lowe's Posts Upbeat Earnings

TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Earnings Scheduled For May 20, 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Market-Moving News for April 2nd

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Immunovant Q3 Earnings Assessment

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

Roivant Signals Major Pipeline Momentum With Accelerated Timelines

Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday

Immunovant Announces Pricing of $550 Million Common Stock Financing

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Insights into Immunovant's Upcoming Earnings

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm